Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Expands Early Access for Genomic Lung Disease Classifier

NEW YORK (GenomeWeb) – Veracyte said yesterday that it has expanded the early-access program (EAP) for its Envisia Genomic Classifier for differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs).

Veracyte launched the EAP in May to provide advance access to the test in anticipation of a nationwide launch in 2019.

Physicians from Banner-University Medical Center Tucson, Cleveland Clinic, Cooper University Health Care, Penn Highlands Healthcare, Tulane University School of Medicine, and University Hospitals Cleveland Medical Center are among the most recent to participate in the Envisia EAP.

They join Jefferson (Philadelphia University and Thomas Jefferson University); Keck Medicine of the University of Southern California; Providence Sacred Heart Medical Center in Washington state; the University of California, Los Angeles; and others. Veracyte said that 20 medical centers in the US are now offering the test through the EAP.

The 190-gene Envisia classifier combines RNA whole-transcriptome sequencing and machine learning to detect the genomic pattern of usual interstitial pneumonia, a hallmark of IPF, with 88 percent specificity and 70 percent sensitivity. The genomic test is performed on patient samples obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation. Veracyte recently received a draft Medicare local coverage decision for Envisia through the MolDX program and anticipates that the policy will become final in early 2019.

"Accurate and timely diagnosis of IPF and other ILDs is often a major challenge for physicians and patients, even with the most advanced imaging technologies," Joseph Lasky of Tulane University School of Medicine said in a statement. "A precise diagnosis is fundamental for developing an optimal patient treatment plan. This may include the use of antifibrotic therapies that are now available to slow progression of IPF, as well as the avoidance of potentially harmful treatments. We are delighted to be one of the first medical centers in the United States to offer this breakthrough genomic technology to our patients."

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.